Journal of Chemotherapy最新文献_第6页

Self-assembled redox-responsive BRD4 siRNA nanoparticles: fomulation and its in vitro delivery in gastric cancer cells. 自组装氧化还原反应BRD4 siRNA纳米颗粒：仿生及其在胃癌细胞中的体外递送。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-01-31 DOI: 10.1080/1120009X.2024.2308980

Mengying Zhang, Zhonghua An, Yiming Jiang, Meijiao Wei, Xiangbo Li, Yifan Wang, Hongbo Wang, Yanling Gong

{"title":"Self-assembled redox-responsive BRD4 siRNA nanoparticles: fomulation and its in vitro delivery in gastric cancer cells.","authors":"Mengying Zhang, Zhonghua An, Yiming Jiang, Meijiao Wei, Xiangbo Li, Yifan Wang, Hongbo Wang, Yanling Gong","doi":"10.1080/1120009X.2024.2308980","DOIUrl":"10.1080/1120009X.2024.2308980","url":null,"abstract":"With the development of newer biomarkers in the diagnosis of gastric cancer (GC), therapeutic targets are emerging and molecular-targeted therapy is in progress RNA interference has emerged as a promising method of gene targeting therapy. However, naked small interfering RNA (siRNA) is unstable and susceptible to degradation, so employing vectors for siRNA delivery is the focus of our research. Therefore, we developed LMWP modified PEG-SS-PEI to deliver siRNA targeting BRD4 (L-NPs/siBRD4) for GC therapy. L-NPs/siBRD4 were prepared by electrostatic interaction and characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM). The release characteristics, cellular uptake and intracellular localization were also investigated. The in vitro anticancer activity of the prepared nanoparticles was analysed by MTT, Transwell invasion and wound healing assay. Quantitative real time-polymerase chain reaction (qRT-PCR) and Western blot were used to detect the effect of gene silencing. The results showed that the optimal N/P was 30 and the prepared L-NPs/siBRD4 uniformly distributed in the system with a spherical and regular shape. L-NPs/siBRD4 exhibited an accelerated release in GSH-containing media from 12h to 24h. The uptake of L-NPs/siBRD4 was enhanced and mainly co-localized in the lysosomes. After 6h incubation, LMWP modified PEG-SS-PEI helped siRNA escape from the lysosomes and diffused into the cytoplasm. L-NPs/siBRD4 significantly inhibited the proliferation, migration and invasion of cells. This might be related with the silence of BRD4, then inhibition of PI3K/Akt and c-Myc. Our results demonstrate that L-NPs/siBRD4 are a novel delivery system with anticancer, which may provide a more effective strategy for GC treatment.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"45-59"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139642230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Co-occurrence of triple carbapenemase genes, bla_VIM-2, bla_NDM-1, and bla_OXA-48 in Enterobacter hormaechei clinical isolates -first report from Croatia. 在霍拉氏肠杆菌临床分离物中同时出现 blaVIM-2、blaNDM-1 和 blaOXA-48 三重碳青霉烯酶基因--克罗地亚的首份报告。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-05-13 DOI: 10.1080/1120009X.2024.2354107

Zrinka Bošnjak, Henrik Hasman, Frank Hansen, Anette M Hammerum, Louise Roer, Ivana Jurić, Ana Budimir

{"title":"Co-occurrence of triple carbapenemase genes, blaVIM-2, blaNDM-1, and blaOXA-48 in Enterobacter hormaechei clinical isolates -first report from Croatia.","authors":"Zrinka Bošnjak, Henrik Hasman, Frank Hansen, Anette M Hammerum, Louise Roer, Ivana Jurić, Ana Budimir","doi":"10.1080/1120009X.2024.2354107","DOIUrl":"10.1080/1120009X.2024.2354107","url":null,"abstract":"Two Enterobacter hormaechei isolates harbouring three carbapenemase genes each, were isolated from two patients from different ICUs at University Hospital Centre Zagreb, Croatia, which is to our knowledge, the first report of triple carbapenemase (blaVIM-2, blaNDM-1, and blaOXA-48) co-existence in E. hormachei strains and also among Enterobacterales members in Croatia. Antimicrobial susceptibility testing showed susceptibility only to colistin and amikacin. The production of carbapenemases was phenotypically tested by immunochromatographic assay and confirmed by PCR. Detailed analysis by Whole Genome Sequencing (WGS) of short reads by Illumina and long reads by Oxford Nanopore Technologies (ONT) was additionally performed and showed that both isolates belonged to ST200. They were separated by 98 Single Nucleotide Polymorphisms (SNPs) having variations in the number of blaVIM-2 genes on the chromosome, the number of blaNDM-1 genes on the plasmid, non-identical blaNDM-1 plasmids, different plasmid content in general, and only one isolate carried a 94 kb prophage.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"10-14"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of bamlanivimab with or without etesevimab and casirivimab-imdevimab in clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. COVID-19患者的临床疗效比较：系统综述和荟萃分析。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-05-09 DOI: 10.1080/1120009X.2024.2352268

Mingyang Yang, Junzhao Liu, Linna Luo, Kaili Dai

引用次数: 0

Clinical value of circulating tumour cells in evaluating the efficacy of continuous hepatic arterial infusion among colorectal cancer patients. 循环肿瘤细胞在评估结直肠癌患者持续肝动脉输注疗效中的临床价值。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-05-06 DOI: 10.1080/1120009X.2024.2333650

Erying Zhang, Haifei Li, Caiyun Liu, Haikun Zhou, Bo Liu, Chengbao Feng

引用次数: 0

Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem. 与头孢吡肟和美罗培南相比，哌拉西林/他唑巴坦与更高的急性肾损伤风险相关。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-01-23 DOI: 10.1080/1120009X.2025.2456327

Nami Obara, Toshiaki Komatsu, Kazuyoshi Shiratsu, Yuto Akamada, Katsuya Otori

引用次数: 0

Therapeutic drug monitoring-guided high-dose isavuconazole therapy for invasive pulmonary aspergillosis in a patient on extracorporeal membrane oxygenation support. 治疗药物监测引导下大剂量异唑康唑治疗侵袭性肺曲霉病1例体外膜氧合支持。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-01-19 DOI: 10.1080/1120009X.2025.2452694

Alba Pau-Parra, Manuel Sosa Garay, Laura Doménech Moral, Mónica Díez Poch, María Martínez Pla, Elisabet Gallart, Jaume Vima Bofarull, Xavier Nuvials, Sonia García-García, Josep María Doménech Vila, Laura Planas Viñuales, Iván Cruz López, Pilar Lalueza Broto, Maria Queralt Gorgas Torner, Ricard Ferrer, Jordi Riera

{"title":"Therapeutic drug monitoring-guided high-dose isavuconazole therapy for invasive pulmonary aspergillosis in a patient on extracorporeal membrane oxygenation support.","authors":"Alba Pau-Parra, Manuel Sosa Garay, Laura Doménech Moral, Mónica Díez Poch, María Martínez Pla, Elisabet Gallart, Jaume Vima Bofarull, Xavier Nuvials, Sonia García-García, Josep María Doménech Vila, Laura Planas Viñuales, Iván Cruz López, Pilar Lalueza Broto, Maria Queralt Gorgas Torner, Ricard Ferrer, Jordi Riera","doi":"10.1080/1120009X.2025.2452694","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2452694","url":null,"abstract":"We review the case of a 58-year-old female on extracorporeal membrane oxygenation (ECMO) support diagnosed with invasive pulmonary aspergillosis (IPA). Intravenous isavuconazole was started, requiring dose escalation to achieve isavuconazole trough concentration (ISA-Cmin) within the therapeutic range (2.5-5.0 μg/mL). For more than 4 months, she maintained a dose of 200 mg q12h, with a median ISA-Cmin of 3.4 (interquartile range [IQR]: 3.1-4.9) µg/mL. Throughout this interval, 17 assessments of ISA-Cmin were performed (weekly). Of these, 82% (14/17) were within the therapeutic range, with an intra-individual variability of 36.8%. Although no signs of hepatotoxicity were observed, she experienced short-term gastrointestinal adverse events related to potential isavuconazole over-exposure (ISA-Cmin > 5.0 μg/mL). ECMO circuit changes did not appear to affect ISA-Cmin. She was not obese (IMC ≈ 25 kg/m2) and did not require other extracorporeal therapy, but hypoalbuminemia may have contributed to an increase in unbound isavuconazole fraction and consequently its clearance.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-01-07 DOI: 10.1080/1120009X.2024.2448644

Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur

{"title":"Immune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers.","authors":"Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur","doi":"10.1080/1120009X.2024.2448644","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2448644","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have shown promise in the treatment of gastric and oesophageal cancers (GEC). Despite their promising efficacy, ICIs have been associated with unique side effects known as immune-related adverse events (IRAEs). Several studies have shown improved treatment responses in patients with IRAEs compared to those without IRAEs in various cancer types such as melanoma and non-small cell lung cancer. We performed a single-institution retrospective study to characterize IRAE incidence and association with treatment response in advanced GEC. We identified 70 patients with GEC who received ICI therapy; 20 (29%) developed an IRAE of any magnitude. The most common were colitis (35%) hypothyroidism (25%) and pneumonitis (20%). Median PFS and OS were not statistically different between IRAE and nonIRAE groups (10.4 vs. 11.3 months p = 0.6 and 11.0 vs. 12.9 months p = 1.0, respectively). This is in contrast to studies in other cancer types that have suggested association between IRAE and improved outcomes.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An acquired CCDC6::RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R)-mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature. 在21外显子EGFR（L858R）突变的非小细胞肺癌中，获得性CCDC6::RET基因融合作为奥西替尼耐药机制，以及奥西替尼和塞尔珀卡替尼的成功治疗：一例报告和文献综述。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2025-01-05 DOI: 10.1080/1120009X.2024.2445909

Maud Lormans, Peter Van Haecke, Ingel Demedts

{"title":"An acquired CCDC6::RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R)-mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature.","authors":"Maud Lormans, Peter Van Haecke, Ingel Demedts","doi":"10.1080/1120009X.2024.2445909","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2445909","url":null,"abstract":"Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are the recommended front-line therapy for treatment-naïve patients with advanced stage EGFR mutated Non-Small Cell Lung Cancer (NSCLC), with better tolerance and outcomes compared to chemotherapy. However, patients inevitably develop resistance to EGFR-TKI. The extent of progression free survival depends on intrinsic or acquired on-target/off-target mechanisms of EGFR-TKI resistance. Overcoming these acquired rearrangements remains challenging in modern precision medicine. In case of disease progression during treatment with an EGFR-TKI, rebiopsy is recommended to search for a potential resistance mechanism. However, the therapeutic potential of these resistance mechanisms represents an unmet need in thoracic oncology. CasePresentation: We present a case of a 78-year-old woman with stage IVB EGFR-mutated NSCLC in whom an acquired RET Gene Fusion was identified as the EGFR-independent resistance mechanism. Additionally, a combined therapy of Osimertinib and Selpercatinib showed a durable oncological response with 14 months of progression free survival in the absence of adverse events. Conclusion: Addition of Selpercatinib to Osimertinib in an EGFR-mutated NSCLC patient with an acquired RET fusion was well tolerated and created a clinical benefit. Further prospective investigation into these novel combination strategies is needed as resistance mechanisms could serve as possible targets for new therapy approaches.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant Pseudomonas aeruginosa strains. 德拉沙星与其他抗多重耐药铜绿假单胞菌菌株的体外相互作用评价。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-26 DOI: 10.1080/1120009X.2024.2445910

Emel Mataracı Kara, Selin Melis Çakmak, Sevda Er

{"title":"Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant Pseudomonas aeruginosa strains.","authors":"Emel Mataracı Kara, Selin Melis Çakmak, Sevda Er","doi":"10.1080/1120009X.2024.2445910","DOIUrl":"https://doi.org/10.1080/1120009X.2024.2445910","url":null,"abstract":"Novel therapeutic interventions are required to address the critical antimicrobial resistance caused by multidrug-resistant Pseudomonas aeruginosa (MDR-PA) infections. This study examines the impact of combining delafloxacin with antibiotics on MDR-PA isolated from various samples. The minimum inhibitory concentrations (MICs) of delafloxacin, alone and in combination with other antibiotics, were determined against forty distinct MDR-PA isolates using the broth microdilution method. Time-kill curve assays were used to determine the bactericidal and synergistic effects of delafloxacin alone and in combination with other antibiotics in vitro against the selected five strains. Our studies showed delafloxacin exhibited four times greater in-vitro activity against MDR-PA strains than levofloxacin compared with both MIC50 and MIC90 results. Delafloxacin + tobramycin and delafloxacin + ceftazidime/avibactam showed synergy in two out of five strains tested at concentrations equal to the MIC. The outcomes of this research also suggest that these combinations may replace therapy for MDR-PA strains.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physiological markers for immunotherapeutics: a review. 免疫治疗生理学标志物研究进展。

IF 1.9 4区医学

Journal of Chemotherapy Pub Date : 2024-12-22 DOI: 10.1080/1120009X.2024.2443701

Durlav Chowdhury, Ashmita Das, Mrityunjay Mishra, Trinkal Khutere, Surendra H Bodakhe

引用次数: 0